Perseus Proteomics Inc
TSE:4882
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
300
833
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Perseus Proteomics Inc
Perseus Proteomics Inc
Net Income
Perseus Proteomics Inc
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Perseus Proteomics Inc
TSE:4882
|
Net Income
-¥1.1B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Net Income
¥8.3B
|
CAGR 3-Years
56%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
|
PeptiDream Inc
TSE:4587
|
Net Income
¥24B
|
CAGR 3-Years
39%
|
CAGR 5-Years
47%
|
CAGR 10-Years
63%
|
|
|
Takara Bio Inc
TSE:4974
|
Net Income
¥841m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-11%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Net Income
¥5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
50%
|
CAGR 10-Years
83%
|
|
|
C
|
Cuorips Inc
TSE:4894
|
Net Income
-¥630m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Perseus Proteomics Inc
Glance View
Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.
See Also
What is Perseus Proteomics Inc's Net Income?
Net Income
-1.1B
JPY
Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Net Income amounts to -1.1B JPY.
What is Perseus Proteomics Inc's Net Income growth rate?
Net Income CAGR 5Y
-47%
Over the last year, the Net Income growth was -40%. The average annual Net Income growth rates for Perseus Proteomics Inc have been -39% over the past three years , -47% over the past five years .
You don't have any saved screeners yet
